Referred to the House Committee on Energy and Commerce.
This bill (Medicaid Breast Cancer Access to Treatment Act) amends Title XIX of the Social Security Act to require Medicaid coverage for certain individuals with breast or cervical cancer by adding a new eligibility category (referencing a revised subsection (aa)). It explicitly adds breast reconstruction following a medically necessary mastectomy to the list of medical assistance covered under Medicaid.
Scope and mandate: liberals view it as necessary expansion for health equity; conservatives see it as an unfunded federal mandate on states.
Relative to its intended legislative type, this bill is a focused substantive change to Medicaid law: it amends specific sections of the Social Security Act to require coverage for certain breast or cervical cancer patients, adds breast reconstruction as a Medicaid benefit, and makes conforming cost-sharing and FMAP changes with a one-year effective date.
This bill (Medicaid Breast Cancer Access to Treatment Act) amends Title XIX of the Social Security Act to require Medicaid coverage for certain individuals with breast or cervical cancer by adding a new eligibility category (referencing a revised subsection (aa)).
It explicitly adds breast reconstruction following a medically necessary mastectomy to the list of medical assistance covered under Medicaid.
The bill makes conforming amendments to federal matching (FMAP) references and to Medicaid cost-sharing rules—adding a cross-reference that items and services furnished to the individuals described in section 1902(aa) are treated under cost-sharing provisions—and updates alternative cost-sharing cross-references.
On content alone, the bill is a narrowly tailored expansion of coverage for a sympathetic medical condition and includes an administrative lead time, which increases its chance of legislative support. However, it constitutes a federal mandate within Medicaid with measurable fiscal impact and requires coordination across statute sections; these features raise opposition risks, particularly in the Senate, and there is no built-in sunset or offsets to mitigate cost concerns—leading to a modest overall likelihood of becoming law.
Relative to its intended legislative type, this bill is a focused substantive change to Medicaid law: it amends specific sections of the Social Security Act to require coverage for certain breast or cervical cancer patients, adds breast reconstruction as a Medicaid benefit, and makes conforming cost-sharing and FMAP changes with a one-year effective date.
Scope and mandate: liberals view it as necessary expansion for health equity; conservatives see it as an unfunded federal mandate on states.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and mandate: liberals view it as necessary expansion for health equity; conservatives see it as an unfunded federal mandate on states.
A mainstream liberal would view this bill favorably as a targeted expansion of access to medically necessary cancer treatment for people who might otherwise lack coverage.
They would note the explicit inclusion of breast reconstruction as closing an important clinical and quality-of-life gap.
The changes to cost‑sharing and FMAP cross-references would be seen as strengthening federal support and reducing financial barriers to care.
A centrist/moderate would generally view the bill as a narrowly targeted health benefit that addresses a clear medical need (cancer treatment and reconstruction), but would seek clarity on costs, eligibility details, and state implementation.
They would appreciate that the bill attempts to align FMAP and cost‑sharing references to make the change administrable, while also flagging the need for fiscal transparency.
They would be open to supporting the bill if funding impacts are reasonable and administrative interactions with existing Medicaid rules are clearly spelled out.
A mainstream conservative would be cautious or opposed because the bill creates a new mandatory coverage requirement within Medicaid and explicitly restricts states' ability to impose certain cost‑sharing for the newly eligible group.
They would view this as an expansion of federal entitlement obligations and potential pressure on state budgets despite FMAP wording.
Some conservatives might accept narrow compassionate exceptions for critical care but would generally prefer state options rather than federal mandates.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a narrowly tailored expansion of coverage for a sympathetic medical condition and includes an administrative lead time, which increases its chance of legislative support. However, it constitutes a federal mandate within Medicaid with measurable fiscal impact and requires coordination across statute sections; these features raise opposition risks, particularly in the Senate, and there is no built-in sunset or offsets to mitigate cost concerns—leading to a modest overall likelihood of becoming law.
The bill has not accumulated any surfaced votes yet.
Scope and mandate: liberals view it as necessary expansion for health equity; conservatives see it as an unfunded federal mandate on states.
On content alone, the bill is a narrowly tailored expansion of coverage for a sympathetic medical condition and includes an administrative…
Relative to its intended legislative type, this bill is a focused substantive change to Medicaid law: it amends specific sections of the Social Security Act to require coverage for certain breast or cervical cancer pati…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.